CN114796125A - Vitamin E powder and preparation method thereof - Google Patents
Vitamin E powder and preparation method thereof Download PDFInfo
- Publication number
- CN114796125A CN114796125A CN202210519700.6A CN202210519700A CN114796125A CN 114796125 A CN114796125 A CN 114796125A CN 202210519700 A CN202210519700 A CN 202210519700A CN 114796125 A CN114796125 A CN 114796125A
- Authority
- CN
- China
- Prior art keywords
- vitamin
- powder
- weight
- ball mill
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 title claims abstract description 140
- 229930003427 Vitamin E Natural products 0.000 title claims abstract description 70
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 title claims abstract description 70
- 229940046009 vitamin E Drugs 0.000 title claims abstract description 70
- 235000019165 vitamin E Nutrition 0.000 title claims abstract description 70
- 239000011709 vitamin E Substances 0.000 title claims abstract description 70
- 239000000843 powder Substances 0.000 title claims abstract description 56
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 42
- 239000000377 silicon dioxide Substances 0.000 claims description 21
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 20
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 19
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 18
- 235000012239 silicon dioxide Nutrition 0.000 claims description 18
- 239000003921 oil Substances 0.000 claims description 13
- 239000000203 mixture Substances 0.000 claims description 12
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- ZAKOWWREFLAJOT-UHFFFAOYSA-N DL-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 claims description 9
- 230000009471 action Effects 0.000 claims description 9
- 238000001514 detection method Methods 0.000 claims description 9
- 238000007873 sieving Methods 0.000 claims description 8
- 235000001809 DL-alpha-tocopherylacetate Nutrition 0.000 claims description 7
- 239000011626 DL-alpha-tocopherylacetate Substances 0.000 claims description 7
- 238000005070 sampling Methods 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 5
- 229940117373 dl-alpha tocopheryl acetate Drugs 0.000 claims description 5
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 4
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 4
- 229910001882 dioxygen Inorganic materials 0.000 claims description 4
- 238000004806 packaging method and process Methods 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 229910052785 arsenic Inorganic materials 0.000 claims description 3
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 claims description 3
- 238000010438 heat treatment Methods 0.000 claims description 3
- 229910001385 heavy metal Inorganic materials 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 2
- 239000001569 carbon dioxide Substances 0.000 claims description 2
- 239000011261 inert gas Substances 0.000 claims description 2
- 229910052751 metal Inorganic materials 0.000 claims description 2
- 239000002184 metal Substances 0.000 claims description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 22
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 235000019198 oils Nutrition 0.000 description 10
- 238000002156 mixing Methods 0.000 description 8
- 229940042585 tocopherol acetate Drugs 0.000 description 8
- 229940088594 vitamin Drugs 0.000 description 8
- 229930003231 vitamin Natural products 0.000 description 8
- 235000013343 vitamin Nutrition 0.000 description 8
- 239000011782 vitamin Substances 0.000 description 8
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical group CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 6
- 238000005469 granulation Methods 0.000 description 6
- 230000003179 granulation Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 4
- 235000001968 nicotinic acid Nutrition 0.000 description 4
- 239000011664 nicotinic acid Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- -1 vitamin nicotinate Chemical class 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229920006316 polyvinylpyrrolidine Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 125000002640 tocopherol group Chemical class 0.000 description 3
- 235000019149 tocopherols Nutrition 0.000 description 3
- GJJVAFUKOBZPCB-ZGRPYONQSA-N (r)-3,4-dihydro-2-methyl-2-(4,8,12-trimethyl-3,7,11-tridecatrienyl)-2h-1-benzopyran-6-ol Chemical class OC1=CC=C2OC(CC/C=C(C)/CC/C=C(C)/CCC=C(C)C)(C)CCC2=C1 GJJVAFUKOBZPCB-ZGRPYONQSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 239000007962 solid dispersion Substances 0.000 description 2
- 230000003381 solubilizing effect Effects 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 229930003802 tocotrienol Natural products 0.000 description 2
- 239000011731 tocotrienol Substances 0.000 description 2
- 229940068778 tocotrienols Drugs 0.000 description 2
- 235000019148 tocotrienols Nutrition 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028289 Muscle atrophy Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000003660 hair regeneration Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 206010019692 hepatic necrosis Diseases 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000003752 improving hair Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000013332 literature search Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000149 liver necrosis Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000020763 muscle atrophy Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 235000018343 nutrient deficiency Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 208000024877 white muscle disease Diseases 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/174—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Animal Husbandry (AREA)
- Zoology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to vitamin E powder and a preparation method thereof, and the preparation method and the production process are improved, so that the balance of water solubility and stability is well realized, and the vitamin E powder is obviously superior to the vitamin E powder prepared by the common preparation process in the prior art.
Description
Technical Field
The invention relates to the fields of biological medicines and food and feed, in particular to vitamin E powder and a preparation method thereof.
Background
Vitamin e (ve) is a generic name for tocopherols, a golden or yellowish oil with a mild, distinctive odor. Vitamin E is generally easily oxidized in the air under illumination to show dark red color. It is miscible with acetone, chloroform, diethyl ether or vegetable oils and practically insoluble in water. Vitamin E is one of the earliest discovered vitamins, is a fat-soluble vitamin necessary for human bodies, is used as an excellent antioxidant and nutrient, and is widely applied to the industries of clinic, medicine, food, feed, health care products, cosmetics and the like. The amount of provitamin E used is greatest in feed additives. About 200-300g of VE in 1KG feed is needed for mixing the feed. The absence of vitamin E supplements can lead to infertility in animals, white muscle disease, nutritional muscle atrophy, liver necrosis, poor growth, nutritional deficiencies, and the like.
There are eight analogues of naturally occurring vitamin E, four tocopherols (tocopherols) and four tocotrienols (tocotrienols), with the highest alpha-tocopherol content and highest physiological activity.
Vitamin E has various biological activities, and has prevention and treatment effects on some diseases. It is a strong antioxidant, can protect the stability of cell membrane by interrupting the chain reaction of free radicals, prevent lipofuscin formation on the membrane and delay the aging of organism; can regulate the metabolic activity of organisms to be performed orderly by maintaining the stability of genetic materials and preventing the structural variation of chromosomes, and also has the function of delaying senescence; can prevent carcinogen from forming in various tissues in vivo, stimulate the immune system of organism, kill newly generated deformed cells, and reverse some malignant tumor cells into cells with normal expression; has effects in maintaining the elasticity of connective tissue, and promoting blood circulation; regulating normal secretion of hormones in vivo; controlling consumption of acid in vivo; protecting skin mucosa, moistening skin, and caring skin; it also has effects in improving hair follicle microcirculation, supplying nutrition, and promoting hair regeneration. Another study showed that vitamin E also prevents LDL cholesterol oxidation and avoids coronary sclerosis. In addition, vitamin E can prevent cataract; delaying alzheimer's disease; maintaining normal reproductive function; maintaining normal state of muscle and peripheral vascular structure and function; treating gastric ulcer; protecting the liver; regulating blood pressure; adjuvant treatment of type II diabetes; has synergistic effect with other vitamins.
Because vitamin E is readily oxidized, the most commonly used vitamin E at present is vitamin E acetate, also known as vitamin E acetate, which is a form of dry vitamin E. The acetate form is more stable than unesterified vitamin E. The difference between the dry vitamin E acetate and the oil form of vitamin E is that the latter has no immediate antioxidant properties.
The formulations of vitamin E currently on the market are of different types, and may be liquid or solid. Vitamin E powder can be used to formulate a variety of solid compositions, and is routinely used in the preparation of food, feed, personal care products, and the like.
The most common method of preparing vitamin E powder is to granulate vitamin E with an adsorbent in an aqueous suspension in a fluidized bed, e.g.EP 1018303A. Mixing vitamin E acetate with gelatin, starch, Tween, etc., dispersing with silicon dioxide or magnesium stearate by ultrahigh pressure micro jet flow dispersion technology to make emulsion particle diameter finer, and spray drying to obtain dry powder (CN 106256346A). Mixing and stirring silicon dioxide and preheated vitamin E oil under reduced pressure to obtain vitamin E powder (CN 101346129A.).
Although there are many studies on the preparation process of vitamin E powder in the prior art, how to improve the stability and water solubility of vitamin E has not been studied.
Disclosure of Invention
The invention provides a preparation method of vitamin E powder, which is physical mixing, avoids the generally adopted spray granulation method in the prior art, avoids the addition of water and an organic solvent, and reduces the process steps. Compared with the spray granulation method, the direct physical mixing granulation method can greatly improve the stability of water solubility, high humidity and extreme conditions (high temperature and high humidity).
The invention provides a preparation method of vitamin E powder, which is characterized in that PEG4000 and PVPK90 are added into silicon dioxide for premixing, so that the stability of high humidity and extreme conditions (high temperature and high humidity) can be maintained on the premise of ensuring that the water solubility is improved.
The invention provides a preparation method of vitamin E powder, which is characterized in that 500 weight parts of silicon dioxide of 300-60 weight parts are mixed with 30-60 weight parts of PEG4000 and 10-20 weight parts of PVPK90, the mixture is heated to 70 ℃, and the mixture is fully mixed and stirred in a ball mill for 10 minutes for premixing; adding 400 portions of DL-alpha-tocopheryl acetate by weight into an oil dissolving kettle, stirring under the protection of non-oxygen gas, heating and preheating to reach a molten state. Adding the vitamin E powder into a ball mill, effectively adsorbing the vitamin E powder with the mixture under the action of mechanochemical force, and sieving to obtain vitamin E powder; 90% of the vitamin E powder can pass through an analysis sieve with the aperture of 0.84 mm; the content of DL-a-tocopheryl acetate is more than or equal to 50.0 percent; heavy metal is less than or equal to 10 mg/kg; the total arsenic (As) is less than or equal to 3 mg/kg.
The preparation method is characterized by comprising the following steps: the ratio of PEG4000 to PVPK90 was 3: 1.
The preparation method is characterized in that: the non-oxygen gas is one or more of nitrogen, inert gas and carbon dioxide.
The preparation method is characterized by further comprising the steps of detection and packaging, wherein mixed batch is carried out after sampling detection is qualified, and metal detection, packaging and warehousing are carried out after detection is qualified.
The preparation method is characterized in that 403 parts by weight of silicon dioxide, 45 parts by weight of PEG4000 and 15 parts by weight of PVPK90 are mixed, heated to 70 ℃, fully mixed and stirred in a ball mill for 10 minutes for premixing; 537 parts by weight of DL-alpha-tocopheryl acetate is added into an oil dissolving kettle, stirred under the protection of nitrogen, heated and preheated to reach a molten state; adding the vitamin E powder into a ball mill, effectively adsorbing the mixture with silicon dioxide and the like under the action of mechanochemical force, and sieving to obtain the vitamin E powder.
The preparation method is characterized in that 403kg of silicon dioxide is mixed with 45kg of PEG4000 and 15kg of PVPK90, the mixture is heated to 70 ℃, and the mixture is fully mixed and stirred in a ball mill for 10 minutes for premixing; 537 kgDL-alpha-tocopheryl acetate is added into an oil dissolving kettle, stirred under the protection of nitrogen, heated and preheated to reach a molten state; adding the vitamin E powder into a ball mill, effectively adsorbing the mixture with silicon dioxide and the like under the action of mechanochemical force, and sieving to obtain the vitamin E powder.
The invention also provides vitamin E powder which is characterized by being prepared by the preparation process.
The vitamin E powder is physically mixed, so that a spray granulation method generally adopted in the prior art is avoided, the addition of water and an organic solvent is avoided, and the process steps are reduced. Compared with the spray granulation method, the direct physical mixing granulation method can greatly improve the stability of water solubility, high humidity and extreme conditions (high temperature and high humidity). The PEG4000 and the PVPK90 are added into the silicon dioxide for premixing, so that the stability under high humidity and extreme conditions (high temperature and high humidity) can be maintained on the premise of ensuring the improvement of water solubility.
Drawings
FIG. 1: process flow diagram
Detailed Description
Example 1:
537 kgDL-alpha-tocopheryl acetate is added into an oil dissolving kettle, stirred under the protection of nitrogen, heated and preheated to reach a molten state; the vitamin E powder is added into a ball mill to be effectively adsorbed with 463kg of silicon dioxide under the action of mechanochemical force, vitamin E powder is obtained by sieving, sampling is carried out according to the quality standard of the vitamin E powder, and the vitamin E powder with the granularity of 90 percent passes through an analysis sieve with the aperture of 0.84 mm.
Comparative example 1:
537 kgDL-alpha-tocopheryl acetate is added into an oil dissolving kettle, stirred under the protection of nitrogen, heated and preheated to reach a molten state; adding silicon dioxide into a fluidized bed, raising the temperature to 50-60 ℃, spraying preheated DL-alpha-tocopherol acetate onto the silicon dioxide in the fluidized bed through a nozzle, mixing and drying to obtain the final vitamin E powder. The detected particle size is 90 percent, and the particle size passes through an analysis sieve with the aperture of 0.84 mm.
The vitamin E powders of example 1 and comparative example 1 were tested and the following data were obtained:
the experiment shows that the vitamin E powder prepared by the mechanochemical method in the patent has similar high-temperature stability and strong illumination stability with the conventional spraying method and has slight advantages. The stability was better in high humidity environment (90% ± 5%, 10 days) and destructive test (90% ± 5%, 10 days). Thus, there are significant advantages. The water solubility of the vitamin E powder prepared by the mechanochemical method in the patent is slightly improved compared with that of the vitamin E powder prepared by the conventional preparation method, but the water solubility is not very obvious. Therefore, the mechanochemical method in the patent can well improve the environment of resisting high humidity and extreme high temperature and high humidity of the vitamin E powder, and the water solubility of the vitamin E powder is also improved to a certain extent.
Example 2: experiment for improving water solubility of vitamin E powder
A common method for improving the water solubility of a substance is to add a solubilizing substance, such as PEG4000, cyclodextrin or to prepare it as a solid dispersion, etc. For this reason, a literature search was conducted, and in CN101084880A, the dissolution rate of vitamin nicotinate in vitro and the absorption degree of vitamin nicotinate in vivo can be improved by preparing vitamin nicotinate and PEG4000 or PVP as solid dispersion. But in example 1-2 by adding 2 times the amount of PEG4000 and 1.5 times the amount of PVP to the vitamin nicotinate. However, it is not guaranteed that more than 50% vitamin E powder can be prepared. Therefore, both schemes are not feasible. For this purpose, the formula is improved and screened, orthogonal experimental screening is carried out, 10, 20, 30, 40, 50 and 60kg of PEG4000, sulfobutyl-beta-cyclodextrin, polyvinylpyrrolidone K90, Tween 80 or the combined auxiliary materials of the two are respectively added into the formula. The specific preparation process comprises the following steps: 537 kgDL-alpha-tocopherol acetate and corresponding solubilizing substances are added into an oil dissolving kettle, stirred, heated and preheated under the protection of nitrogen to reach a molten state; adding the vitamin E powder into a ball mill, effectively adsorbing the vitamin E powder with the balance of silicon dioxide (total 1000kg) under the action of mechanochemical force, and sieving to obtain the vitamin E powder.
Experiments show that the water solubility can be greatly increased under the condition of adding 60kg of PEG4000 and polyvinylpyrrolidone K90 at a ratio of 3:1, and the water solubility can reach 43 mu g/mL. But the stability under high humidity and destructive test was reduced to 91.1% and 87.64%, respectively. Therefore, it is necessary to consider how to improve the stability thereof while maintaining the increased water solubility.
Example 3: experiment for improving stability of vitamin E powder
During the continuous screening and experiment process, the silicon dioxide, PEG4000 and polyvinylpyrrolidone K90(PEG 4000: K90 ═ 3:1) are firstly premixed in a ball mill under the heating state; then the powder is prepared with DL-alpha-tocopherol acetate, which can improve the stability and has no obvious reduction of water solubility.
The preparation method comprises the following steps:
403kg of silica was mixed with 45kg of PEG4000 and 15kg of PVPK90, heated to 70 ℃ and thoroughly mixed and stirred in a ball mill for 10 minutes for premixing. 537 kgDL-alpha-tocopherol acetate is added into an oil dissolving kettle, stirred under the protection of nitrogen, heated and preheated to reach a molten state. The vitamin E powder is added into a ball mill and is effectively adsorbed with a mixture of silicon dioxide and the like under the action of mechanochemical force, vitamin E powder is obtained through screening, and the water solubility and the stability of the vitamin E powder are tested by sampling.
Therefore, through the improvement of the process, the water solubility can be improved and the excellent stability can be realized after the PEG4000 PVPK90 is added. Its improved water solubility was not as good as example 2 and stability was not as good as example 1, but it achieved a balance of water solubility and stability. And sampling and detecting according to the vitamin E powder, and uniformly mixing and then detecting according to the quality standard of a finished product of the vitamin E powder. The drying weight loss is less than or equal to 5 percent through detection; the particle size of 90 percent passes through an analysis sieve with the aperture of 0.84 mm; heavy metal is less than or equal to 10 (mg/kg); the total arsenic (As) is less than or equal to 3 (mg/kg).
The foregoing description is a general description of the invention. Changes in form and substitution of equivalents may be made as circumstances or practical, and although specific terms are employed herein, they are intended in a descriptive sense and not for purposes of limitation. Various changes or modifications may be effected therein by one skilled in the art and equivalents may be made thereto without departing from the scope of the invention as defined in the claims appended hereto.
Claims (6)
1. A preparation method of vitamin E powder is characterized in that 300-500 parts by weight of silicon dioxide, 30-60 parts by weight of PEG4000 and 10-20 parts by weight of PVPK90 are mixed, heated to 70 ℃, fully mixed and stirred in a ball mill for 10 minutes for premixing; adding 400 portions of DL-alpha-tocopheryl acetate by weight and 600 portions of DL-alpha-tocopheryl acetate into an oil dissolving kettle, stirring under the protection of non-oxygen gas, heating and preheating to reach a molten state; adding the vitamin E powder into a ball mill, effectively adsorbing the vitamin E powder with the mixture under the action of mechanochemical force, and sieving to obtain vitamin E powder; 90% of the vitamin E powder can pass through an analysis sieve with the aperture of 0.84 mm; the content of DL-a-tocopheryl acetate is more than or equal to 50.0 percent; heavy metal is less than or equal to 10 mg/kg; the total arsenic (As) is less than or equal to 3 mg/kg.
2. The method of claim 1, wherein: the ratio of PEG4000 to PVPK90 was 3: 1.
3. The method of claim 1, wherein: the non-oxygen gas is one or more of nitrogen, inert gas and carbon dioxide.
4. The preparation method according to claim 1, further comprising the steps of detection and packaging, wherein the sampling detection is qualified, the mixed batch is carried out, and the metal detection, packaging and warehousing are carried out after the sampling detection is qualified.
5. The process according to claim 1, wherein 403 parts by weight of silica is mixed with 45 parts by weight of PEG4000 and 15 parts by weight of PVPK90, heated to 70 ℃, thoroughly mixed and stirred in a ball mill for 10 minutes to carry out premixing; 537 parts by weight of DL-alpha-tocopheryl acetate is added into an oil dissolving kettle, stirred under the protection of nitrogen, heated and preheated to reach a molten state; adding the vitamin E powder into a ball mill, effectively adsorbing the mixture with silicon dioxide and the like under the action of mechanochemical force, and sieving to obtain the vitamin E powder.
6. The preparation method according to claim 1, wherein 403kg of silica is mixed with 45kg of PEG4000 and 15kg of PVPK90, heated to 70 ℃, fully mixed and stirred in a ball mill for 10 minutes for premixing; 537 kgDL-alpha-tocopheryl acetate is added into an oil dissolving kettle, stirred under the protection of nitrogen, heated and preheated to reach a molten state; adding the vitamin E powder into a ball mill, effectively adsorbing the mixture with silicon dioxide and the like under the action of mechanochemical force, and sieving to obtain the vitamin E powder.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210519700.6A CN114796125A (en) | 2022-05-12 | 2022-05-12 | Vitamin E powder and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210519700.6A CN114796125A (en) | 2022-05-12 | 2022-05-12 | Vitamin E powder and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114796125A true CN114796125A (en) | 2022-07-29 |
Family
ID=82514609
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210519700.6A Pending CN114796125A (en) | 2022-05-12 | 2022-05-12 | Vitamin E powder and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN114796125A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3895757B1 (en) * | 2005-12-29 | 2007-03-22 | 東亜薬品株式会社 | Powdered composition |
| CN101084880A (en) * | 2006-06-09 | 2007-12-12 | 中国人民解放军军事医学科学院毒物药物研究所 | Biological solid dispersion of vitamin E esters derivatives and preparation method thereof |
| CN106937699A (en) * | 2017-03-23 | 2017-07-11 | 陕西金冠牧业有限公司 | A kind of preparation method of feeding nanometer vitamin E powder |
| CN109718206A (en) * | 2017-10-31 | 2019-05-07 | 大丰海嘉诺药业有限公司 | A method of producing vitamin E powder |
-
2022
- 2022-05-12 CN CN202210519700.6A patent/CN114796125A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3895757B1 (en) * | 2005-12-29 | 2007-03-22 | 東亜薬品株式会社 | Powdered composition |
| CN101084880A (en) * | 2006-06-09 | 2007-12-12 | 中国人民解放军军事医学科学院毒物药物研究所 | Biological solid dispersion of vitamin E esters derivatives and preparation method thereof |
| CN106937699A (en) * | 2017-03-23 | 2017-07-11 | 陕西金冠牧业有限公司 | A kind of preparation method of feeding nanometer vitamin E powder |
| CN109718206A (en) * | 2017-10-31 | 2019-05-07 | 大丰海嘉诺药业有限公司 | A method of producing vitamin E powder |
Non-Patent Citations (1)
| Title |
|---|
| 吴正红主编, 中国医药科技出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101255874B1 (en) | Nanosized carotenoid cyclodextrin complexes | |
| JP3914619B2 (en) | Stable emulsions and dry powders of fat-soluble vitamin mixtures, their production, their use and foodstuffs, pharmaceuticals or animal feeds containing them | |
| EP0982038B1 (en) | Stable powdery vitamin and carotenoide containing compositions and process to prepare them | |
| JP2000103733A (en) | Stable lycopene powder preparation, stable aqueous dispersion of lycopene, their production, use thereof, and nutrient assisting agent, animal feed, food, pharmaceutical and cosmetic containing the same | |
| JP2003516720A (en) | Stable carotene-xanthophyll beadlet compositions and methods of use | |
| DE202006020886U1 (en) | Algae and algae extract dietary supplement composition | |
| CN109418541B (en) | Preparation method of hydrophobic fat-soluble vitamin microcapsule | |
| EP1450628A1 (en) | Powder formulation comprising conjugated octadecapolyenic acids | |
| WO2007063095A1 (en) | Use of zinc salts of lipoic acid for treating fat metabolism disorders | |
| US20080085330A1 (en) | Compounds for stimulating stem cell proliferation including spirulina | |
| Wang et al. | Effect of high pressure treatment on rapeseed protein microparticle properties and gastrointestinal release behavior of the encapsulated peptides | |
| JP5264107B2 (en) | Composition having antioxidative action | |
| AT406935B (en) | METHOD FOR PRODUCING AN OILY PREPARATION | |
| EP2060256A1 (en) | Pharmaceutical and nutraceutical compositions based on menaquinols | |
| CN114796125A (en) | Vitamin E powder and preparation method thereof | |
| JP2022000030A (en) | Neuronal differentiation promoter, and neuronal differentiation promoting composition | |
| CN114886122B (en) | Preparation method of vitamin E powder with improved performance | |
| JPH04139132A (en) | Anti-active oxygen action composition, anti-active oxygen agent, food, cosmetic and medicine containing the same as active ingredient | |
| JP5341422B2 (en) | Antioxidant composition containing bee candy and royal jelly | |
| KR102483142B1 (en) | Multi-vitamins complex composition with improved compliance through size reduction for formulation using iLet(innovative Low excipient tablet) technology and preparation method for the same | |
| US20080089905A1 (en) | COMPOUNDS FOR STIMULATING STEM CELL PROLIFERATION INCLUDING AFA-OMEGA (EtOH) | |
| DE3446887C2 (en) | Process for the production of physiologically active, water-soluble hemin arginate or hemin lysinate | |
| KR20140068488A (en) | Formation of tocopherol-starch nano-complex and functional beverage comprising the same | |
| AU2021106478A4 (en) | Vitamin D3 Compositions | |
| JP5264106B2 (en) | Composition having antioxidative action |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: 322121 Huayuan Village, Nanma Town, Jinhua City, Zhejiang Province Applicant after: Zhejiang Garden Biopharmaceutical Co.,Ltd. Address before: 322121 Huayuan village, Nanma Town, Dongyang City, Jinhua City, Zhejiang Province Applicant before: ZHEJIANG GARDEN BIOCHEMICAL HIGH-TECH Co.,Ltd. |
|
| CB02 | Change of applicant information |